Zoetis (ZTS) Non-Current Deferred Tax Liability (2012 - 2026)
Zoetis (ZTS) reported Non-Current Deferred Tax Liability of $130.0 million for Q1 2026, down 19.25% year-over-year from $161.0 million in Q1 2025, and down 5.11% quarter-over-quarter from $137.0 million in Q4 2025.
Zoetis (ZTS) Non-Current Deferred Tax Liability (2012 - 2026) Analysis & Trends
Zoetis (ZTS) has 15 years of Non-Current Deferred Tax Liability data on file, last reported at $130.0 million in Q1 2026.
- Non-Current Deferred Tax Liability for Q1 2026 came in at $130.0 million, down 19.25% year-over-year; the trailing twelve-month figure through Mar 2026 was $130.0 million (down 19.25% YoY), and the FY2025 annual result was $137.0 million, down 17.96% from the prior year.
- Non-Current Deferred Tax Liability declined to $130.0 million in Q1 2026 per ZTS's latest filing, from $137.0 million in the prior quarter.
- Over five years, Non-Current Deferred Tax Liability peaked at $287.0 million in Q1 2022 and troughed at $121.0 million in Q2 2023.
- A 5-year average of $170.5 million and a median of $156.0 million in 2025 frame the typical range for Non-Current Deferred Tax Liability.
- The sharpest annual moves came in 2023 and 2024: Non-Current Deferred Tax Liability slumped 55.84% in 2023, then soared 44.63% in 2024.
- A 5-year view of Non-Current Deferred Tax Liability shows it stood at $142.0 million in 2022, then rose by 2.82% to $146.0 million in 2023, then rose by 14.38% to $167.0 million in 2024, then slipped by 17.96% to $137.0 million in 2025, then dropped by 5.11% to $130.0 million in 2026.
- Business Quant data shows ZTS's Non-Current Deferred Tax Liability at $130.0 million in Q1 2026, $137.0 million in Q4 2025, and $147.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn |
| 10 | Liquidia | 5.64 Bn | 5.42 Bn | 121.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 130.00 Mn |
| Mar 31, 2026 | 130.00 Mn |
| Dec 31, 2025 | 137.00 Mn |
| Dec 31, 2025 | 137.00 Mn |
| Sep 30, 2025 | 147.00 Mn |
| Sep 30, 2025 | 147.00 Mn |
| Jun 30, 2025 | 156.00 Mn |
| Jun 30, 2025 | 156.00 Mn |
| Mar 31, 2025 | 161.00 Mn |
| Mar 31, 2025 | 161.00 Mn |
| Dec 31, 2024 | 167.00 Mn |
| Dec 31, 2024 | 167.00 Mn |
| Sep 30, 2024 | 172.00 Mn |
| Sep 30, 2024 | 172.00 Mn |
| Jun 30, 2024 | 175.00 Mn |
| Jun 30, 2024 | 175.00 Mn |
| Mar 31, 2024 | 136.00 Mn |
| Mar 31, 2024 | 136.00 Mn |
| Dec 31, 2023 | 146.00 Mn |
| Dec 31, 2023 | 146.00 Mn |